+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orexo AB - logo

Orexo AB is a specialty pharmaceutical company in the United States. Its launched products include Zubsolv sublingual tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. It has collaboration agreement with Mundipharma for the development and commercialization of Zubsolv and with AstraZeneca with regards to the OX-Cysteinyl Leukotriene Inhibitor project. Founded in 1995, the company is headquartered in Uppsala, Sweden.

Opioid Drugs: Global Markets to 2023 - Product Thumbnail Image

Opioid Drugs: Global Markets to 2023

  • Report
  • November 2018
  • 147 Pages
From
From
From
Global Addictions Therapeutics Market 2021-2025 - Product Thumbnail Image

Global Addictions Therapeutics Market 2021-2025

  • Report
  • January 2021
  • 120 pages
From
Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • February 2020
  • 437 pages
From
From
From
Zubsolv 2019 U.S. Promotional Audit Report - Product Thumbnail Image

Zubsolv 2019 U.S. Promotional Audit Report

  • Report
  • July 2020
  • 30 pages
From
Opium (Opioid) Addiction - Pipeline Review, H2 2020 - Product Thumbnail Image

Opium (Opioid) Addiction - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 193 pages
From
Drug Overdose - Pipeline Review, H2 2020 - Product Thumbnail Image

Drug Overdose - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 79 pages
From
Loading Indicator
adroll